Key points are not available for this paper at this time.
Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.
Building similarity graph...
Analyzing shared references across papers
Loading...
David M. Williams
Swansea Bay University Health Board
Barbara-Alex Alberts
Swansea Bay University Health Board
Asem Sharaf
Swansea Bay University Health Board
Diabetes Therapy
Swansea University
Singleton Hospital
Morriston Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Williams et al. (Thu,) studied this question.
synapsesocial.com/papers/68e6ac60b6db64358762f194 — DOI: https://doi.org/10.1007/s13300-024-01590-x